Clinical Trials

Inclusion Criteria

• Must be greater than 18 years of age
• Must be able to provide informed consent
• Must have KRAS/NRAS/BRAF wild-type colorectal cancer
• Is willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 120 days following the last dose of any study therapy
  • Applies to women of childbearing potential as well as fertile men and their partners

Exclusion Criteria

• Has had previous pelvic radiation treatment
• Pregnant or lactating
• Untreated (primary) or uncontrolled Central Nervous System (CNS) (primary or metastatic) malignancies
  • CNS metastases that have undergone surgery or radiotherapy or have been on a stable dose of corticosteroids for at least 2 weeks, and with stable disease prior to the first scheduled day of dosing will be eligible for the trial
• History of any second malignancy in the last 3 years 
  • Prior history of in-situ cancer or basal or squamous cell skin cancer are eligible
• Has received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days or bevacizumab within 28 days, and has passed the time of any actual or anticipated toxicities prior to the first scheduled dose of the study treatment